eCite Digital Repository

Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand

Citation

Claflin, S and Campbell, JA and Norman, R and Mason, DF and Kalincik, T and Simpson-Yap, S and Butzkueven, H and Carroll, WM and Palmer, AJ and Blizzard, CL and van der Mei, I and Henson, GJ and Taylor, BV, Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand, The European Journal of Health Economics Article ePub ahead of print. ISSN 1618-7598 (2022) [Refereed Article]

Copyright Statement

The Author(s) 2022.

DOI: doi:10.1007/s10198-022-01518-x

Abstract

Background: Health state utilities (HSU) are a health-related quality-of-life (HRQoL) input for cost-utility analyses used for resource allocation decisions, including medication reimbursement. New Zealand (NZ) guidelines recommend the EQ-5D instruments; however, the EQ-5D-5L may not sufficiently capture psychosocial health. We evaluated HRQoL among people with multiple sclerosis (MS) in NZ using the EQ-5D-5L and assessed the instrument's discriminatory sensitivity for a NZ MS cohort.

Methods: Participants were recruited from the NZ MS Prevalence Study. Participants self-completed a 45-min online survey that included the EQ-5D-5L/EQ-VAS. Disability severity was classified using the Expanded Disability Status Scale (EDSS) to categorise participant disability as mild (EDSS: 0-3.5), moderate (EDSS: 4.0-6.0) and severe (EDSS: 6.5-9.5). Anxiety/depression were also measured using the Hospital Anxiety and Depression Score (HADS). In the absence of an EQ-5D-5L NZ tariff, HSUs were derived using an Australian tariff. We evaluated associations between HSUs and participant characteristics with linear regression models.

Results: 254 participants entered the study. Mean age was 55.2 years, 79.5% were female. Mean (SD) EQ-5D-5L HSU was 0.58 (0.33). Mean (SD) HSUs for disability categories were: mild 0.80 +- 0.17, moderate 0.57 +- 0.21 and severe 0.14 +- 0.32. Twelve percent reported HSU = 1.0 (i.e., no problems in any domain). Participants who had never used a disease-modifying therapy reported a lower mean HSU. Multivariable modelling found that the HADS anxiety score was not associated with EQ-5D-5L.

Conclusions: for people with MS in NZ was lower than comparable countries, including Australia. We suggest a comparison with other generic tools that may have improved sensitivity to mental health.

Item Details

Item Type:Refereed Article
Keywords:multiple sclerosis, quality of life, EQ-5D-5L, economic evaluation, health technology assessment, neurology
Research Division:Economics
Research Group:Applied economics
Research Field:Health economics
Objective Division:Health
Objective Group:Evaluation of health and support services
Objective Field:Evaluation of health outcomes
UTAS Author:Claflin, S (Dr Suzi Claflin)
UTAS Author:Campbell, JA (Dr Julie Campbell)
UTAS Author:Simpson-Yap, S (Dr Steve Simpson JR)
UTAS Author:Palmer, AJ (Professor Andrew Palmer)
UTAS Author:Blizzard, CL (Professor Leigh Blizzard)
UTAS Author:van der Mei, I (Professor Ingrid van der Mei)
UTAS Author:Henson, GJ (Mr Glen Henson)
UTAS Author:Taylor, BV (Professor Bruce Taylor)
ID Code:153552
Year Published:2022
Deposited By:Menzies Institute for Medical Research
Deposited On:2022-09-24
Last Modified:2023-01-13
Downloads:0

Repository Staff Only: item control page